Lyell Immunopharma Inc. announced a reverse stock split at a ratio of 1-for-20, effective May 30, 2025. This move will consolidate every 20 shares of the company's common stock into one share, without altering the par value per share. The company's stock will trade on a split-adjusted basis on the Nasdaq Global Select Market starting June 2, 2025, under the new CUSIP number 55083R203. Following the split, the number of outstanding shares will reduce from approximately 296 million to around 14.8 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.